show episodes
 
The power of data is remaking everything in healthcare—not just the way doctors diagnose patients, but the way pharma companies develop drugs and the way hospitals and insurers control costs and create value. Here at MoneyBall Medicine, host Harry Glorikian talks with the executives, entrepreneurs, physicians, and scientists who are pushing that high-tech revolution forward. Harry's 2017 book "MoneyBall Medicine" offered an inside look at the ways genomics, machine learning, and other trends ...
 
Loading …
show series
 
Michael Geer is co-founder and CSO (Chief Strategy Officer) of Humanity Health, a London-based startup that's building an iPhone app and subscription service designed to help users slow or reverse their rate of aging. Geer's co-founder Pete Ward has described the app as like “Waze for maximizing health span," or years of healthy functioning. The Hu…
 
This week on MoneyBall Medicine, Harry takes a field trip (literally!) into farming and agriculture. His guests are Al Eisaian co-founder and CEO of crop intelligence IntelinAir, and the company’s director of machine learning, Jennifer Hobbs. Intelinair’s AGMRI platform uses customized computer vision and deep learning algorithms to sift through te…
 
What if there were a single company that could connect hospital electronic health record systems to a massive genomic testing and analytics platform? It would be a little like Amazon Web Services (AWS) for healthcare—an enabling platform for anyone who wants to deploy precision medicine at scale. That's exactly what Joel Dudley says he's now helpin…
 
This week Harry catches up with Christine Lemke from Evidation Health, a startup in San Mateo, CA, that helps drug developers and other organizations analyze the effectiveness of smart devices and wearables in new types of therapies. Lemke is Evidation's co-CEO. Our Fitbits and Apple Watches are with us so much of the time that the data they collec…
 
Thomas Chittenden, chief data science officer at Genuity Science, says what's keeping the genomics revolution from turning into an equivalent revolution in drug discovery is that most of our domain knowledge about the molecular biology of disease has come from a hunt-and-peck approach, focused on one gene at a time. Find some gene relevant to a dis…
 
This week Harry interviews the head of Etiometry, a Boston-based startup building visualization systems and decision support software for hospital intensive care units. Shane Cooke says critical care "is an incredibly complex environment where speed matters and information matters." By aggregating real-time data, lab results, and historical patient…
 
Charles Fisher is the founder and CEO at Unlearn, a San Francisco company using purpose-built machine learning algorithms that use historical clinical trial data to create "digital twins" of actual participants in controlled drug trials to help predict how each participant would have fared if they'd been given a placebo. By comparing a patient's ac…
 
What if all our everyday assumptions about economics are wrong? This week Harry speaks with author and entrepreneur Jeff Booth, who says the most powerful force for change in the future will be deflation: getting more for less. Even the healthcare industry will feel the effects, he says. Listen to find out how. Booth is the author of The Price of T…
 
How does an expert in pharmacokinetics, whose only exposure to computers was taking one semester of programming in college to meet a language requirement, become an advocate for the new AI-driven style of drug discovery? This week Harry finds out from Mark Eller, who helped to invent Allegra at Hoechst Marion Roussel (now Sanofi), spent 12 years at…
 
Harry welcomes back Andrew A. Radin, CEO of the drug discovery startup twoXAR, where scientists model pathogenesis computationally to identify potential drug molecules, ideally shaving years off the drug development process. Harry first spoke with Radin two years ago at the AI Applications Summit—Biopharma. (Listen back to MoneyBall Medicine Episod…
 
In this week's show Harry interviews Rayid Ghani, a computer scientist at Carnegie Mellon University who studies how to use AI and data science to model and influence people's behavior in realms like politics, healthcare, education, and criminal justice. Ghani tell Harry he grew up hating coding, since the very need for it showed that "computers ar…
 
This week Harry speaks with Oura Health CEO Harpreet Rai, who's leading an effort to explore how a wearable sleep-monitoring device—the Oura Ring—can pick up patterns that may help diagnose covid-19 infections and other problems. The ring is equipped with sensors that measure heart rate and body temperature, as well as a tiny Bluetooth radio that s…
 
David Sable got his start in reproductive medicine in the late 1980s, a time when he says fertility treatments were "very primitive." But by the mid-2000s, he says, new procedures and new insights into the genetics of development had changed everything. His subsequent time observing (and investing in) the field has convinced him that reproductive m…
 
This week Harry speaks with molecular geneticist Elli Papaemmanuil about how newly available genomic data could lead to major improvements in the standard of care for cancer patients, leading to an age of true precision medicine. Papaemmanuil is an assistant professor of computational oncology at Memorial Sloan Kettering Cancer Center in New York. …
 
This week Harry interviews Gregory Bowman, an associate professor in the department of biochemistry and molecular biophysics in the School of Medicine at Washington University in St. Louis. Bowman is the current director of Folding@home, a distributed computing project currently focused on analyzing the structures of coronavirus proteins to find ta…
 
Harry's guest this week is the founder and CEO of a New Zealand firm, SaferMe, that had developed proximity-based smartphone apps for worker safety. When the coronavirus came along, their apps turned out to be a great way to help companies build their own "contact tables" to identify, test, and isolate SARS-CoV-2 carriers. In epidemiology, contact …
 
Though the p-value "determines everything we do in drug development or medical research," says Dr. Ulo Palm , it may be one of the most misunderstood and misused quantities in experimental science—drug discovery included. At its core, the p-value shows the probability that an observed effect was due to random chance. In other words, if a drug seems…
 
Building on his March 2020 interview with Jake Glanville, the founding partner and CEO of South San Francisco-based computational antibody engineering startup Distributed Bio, Harry speaks with three company scientists in the trenches: JP Buerckert, director of computational immunology, and Shahrad Daraekia and Jack Wang, both senior scientists. To…
 
If you've seen the recent Netflix docu-series "Pandemic," about efforts to check previous viral outbreaks, you've seen former Pfizer scientist Jacob Glanville in action. The inventor, entrepreneur, and Ph.D. immunologist capitalized on the advent of cloud computing to provide vaccine and drug developers with high-throughput genomic sequencing of an…
 
Schrödinger makes software that models the physics of atomic-scale interactions to predict the chemical properties of candidate drug molecules, helping its customers speed up drug discovery. A decade ago, Farid tells Harry, the company faced the chicken-and-egg challenge of convincing customers that its computational platform works, so that they wo…
 
Rapid sequencing of viral genomes is giving physicians and epidemiologists new ways to identify, track, and potentially slow outbreaks of viral infections such as the novel Wuhan coronavirus. That means high-throughput genome sequencing—which had predominantly been a research tool—is taking its place as a front-line weapon in the fight to prevent p…
 
Doctors helping couples conceive through in-vitro fertilization typically must screen multiple fertilized embryos to select one embryo for implantation—but the process is fraught with risk and subjectivity. from In 2018 Gilboa and her colleagues Daniel Seidman and Eyal Schiff co-founded AIVF, an Israel-based startup developing decision support tool…
 
Tom Davenport knows analytics, big data, and AI—he teaches executive courses on the subject at Babson College, Harvard Business School, the Harvard School of Public Health, and the MIT Sloan School of Management, and is widely known for his books on analytics and AI in business, Competing on Analytics (2007), Only Humans Need Apply (2016), and The …
 
Milind Kamkolkar joined Cellarity in January 2019 to help the company to prove that it is now possible to "encode a cell" digitally—to use big data, deep learning, and other methods to model many different interconnected networks of molecular interactions. "The whole idea...is really only feasible now," he says. "What changed over the last number o…
 
Dr. Alan Copperman is director of the Division of Reproductive Endocrinology and Infertility and Vice Chairman of the Department of Obstetrics, Gynecology, and Reproductive Science at the Mount Sinai Health System. He's also a clinical professor of Obstetrics, Gynecology, and Reproductive Science at the Icahn School of Medicine at Mount Sinai; medi…
 
Gini Desphande says she likes to think of "AI" as augmented intelligence rather than artificial intelligence: a system of human plus machine intelligence that can speed up drug development and cut R&D costs and failure rates in clinical trials. AI "really isn't at the point where it's automatable," she says. "We still need a lot of human intelligen…
 
Dr. Chris Boone, vice president and lead for global medical epidemiology and big data analysis at Pfizer, is a health futurist, social entrepreneurs, executive, professor, patient advocate, and self-proclaimed "data hippie." He says he long aimed to be CEO of a health system, but eventually embraced his "true self" as a student of informatics, busi…
 
Harry talks with Kevin Tabb, MD, the CEO and president of Beth Israel Lahey Health, the product of Lahey Health's merger this spring with Beth Israel Deaconess Medical Center (BIDMC) and several other hospitals in the Boston region. How does Dr. Tabb manage change inside a growing organization that—by his own admission—has to build and implement ne…
 
Harry talks this week with Salesforce's vice president of strategic research, Peter Coffee. The computer-industry veteran and former tech columist says that in the era of 1) outcomes-based payments for medical care, 2) an aging patient base, and 3) ubiquitous sensors and continuous data collection, there's a huge opportunity—and financial incentive…
 
As one of the researchers involved in the 70-year-long Framingham Heart Study, Rhoda Au is in a unique position to investigate whether changes in speech patterns in middle-aged people could prefigure the onset of Alzheimer’s disease later in life, and whether early detection might give patients more time to take preventative measures. She’s been pa…
 
Kathryn Teng, MD, is division chief of internal medicine and community medicine at MetroHealth, one of three major healthcare systems serving Cleveland and the rest of Cuyahoga County in Ohio. She believes that healthcare costs are out of control in part because too many patients go directly to specialists about issues that their primary care physi…
 
Many of the processes carried out in traditional chemistry labs searching for new drugs or drug targets can be sped up through factory-style automation—and in fact, “combinatorial chemistry” was a big boost for the field. But Alán Aspuru-Guzik, a theoretical chemist in the departments of chemistry and computer science at the University of Toronto, …
 
Dr. Jennifer Carter says it was watching friends and family members stricken with cancer struggle navigate the complexities of the healthcare system in the early 2000s that inspired her to start a company in the area of precision medicine. At that time, the development of targeted therapies for cancers with specific genetic markers was already offe…
 
Adjusting to a more collaborative style may take doctors some time, says Dr. Mark Boguski, but if they stop confining themselves to disciplinary boundaries, they'll be able to see connections between different areas of medicine that aren't taught in medical schools. Boguski draws on examples from oncology, where he says doctors are gradually being …
 
Harry's guest Sandy Aronson argues that AI and apps are not the solution for better healthcare; more effective care workflows enabled by AI and apps are the solution. Aronson is the executive director of information technology at Partners HealthCare Personalized Medicine. His team develops the IT infrastructure needed to support genetic-based perso…
 
What if we could use machine learning to train software to read CT scans of patients with intracranial hemorrhaging? Time to diagnosis could be doubled, potentially saving lives. This week Harry discusses such questions with Dr. Aalpen Patel, a physician-engineer who chairs Geisinger's department of radiology and directs is 3D imaging and printing …
 
Harry's guest in this episode is Massimo Buscema, director of the Semieon Research Center in Rome, Italy, and a full professor at the University of Colorado at Denver. Buscema researches and consults internationally on the theory and applications of AI, artificial neural networks, and evolutionary algorithms. The conversation focuses on AI and its …
 
Harry's guest for this episode is Dr. Barrett Rollins, the chief scientific officer and faculty dean for academic affairs at Boston's Dana Farber Cancer Institute and the Linde Family Professor of Medicine at Harvard Medical School. Harry and Dr. Rollins dig into how large-scale DNA analysis can one day put much more usable information into the han…
 
Harry's guest this week is Dr. Joel Dudley from the Icahn School of Medicine at Mount Sinai, where he serves as executive vice president of precision health, associate professor of genetics and genomic sciences, and founding director of the Institute for Next Generation Healthcare. Dr. Dudley explains how his group is utilizing data to uncover heal…
 
Harry talks with Wim Van Hecke, the founder and CEO of Icometrix—builder of a cloud-based AI platform for analyzing brain MRI and CT scans—to find out how the startup's FDA-cleared technology is changing the way radiologists and other physicians interpret neuroimaging data. How to rate MoneyBall Medicine on iTunes with an iPhone, iPad, or iPod touc…
 
Harry's guest this week, Dr. Robert Green, is a professor of medicine and genetics at Harvard Medical School and director of the Genomes To People research program at Brigham & Women's Hospital and the Broad Institute of Harvard and MIT. They dig into the individual genome, how genomic data is being used, and the impact of genomics on various stake…
 
Harry talks with Sharon Terry, president and CEO of Genetic Alliance, about the way drug discovery, diagnostics , and the treatment of patience are changing. How to rate MoneyBall Medicine on iTunes with an iPhone, iPad, or iPod touch: Launch the "Podcasts" app on your device. If you can't find this app, swipe all the way to the left on your home s…
 
Today's radiologists face a deluge of data, and their work can be tedious and error-prone. But should humans even act as radiologists? It's becoming clear that computers and humans working together are better than either alone. Harry's guest this week is Fabien Beckers, CEO of Arterys, a startup creating products at the intersection of AI, the clou…
 
Harry speaks with Wout Brusselaers, CEO and founder of Deep6.AI, about new technology that could help find patients for clinical trials in minutes rather than months. This is Part 6 of a six-part special series recorded at the AI Applications Summit, produced in Boston by Corey Lane Partners in October 2018. How to rate MoneyBall Medicine on iTunes…
 
Harry's guest is Guido Lanza, president and CEO of Numerate. Together they tackle the question: What if the introduction of AI into drug discovery allowed us to create a true learning loop? This is Part 5 of a special six-part series recorded at the AI Applications Summit, produced in Boston by Corey Lane Partners in October 2018. How to rate Money…
 
Harry asks Dr. Ron Alfa, vice president of discovery and product at Recursion Pharmaceuticals, what efficiencies could be achieved and what problems could be solved if data science were applied to drug discovery. This is Part 4 of a special six-part series recorded at the AI Applications Summit, produced in Boston by Corey Lane Partners in October …
 
Harry's guest is Dr. Shrujal Baxi, medical director of Flatiron Health. On the agenda: how technology can help create the real-world evidence needed to achieve better patient outcomes and accelerate research into new areas. This is Part 3 of a 6-part special series recorded at the AI Applications Summit, produced in Boston by Corey Lane Partners in…
 
In this episode Harry talks with Milind Kamkolkar, chief data officer at Sanofi, about how big pharma can start using new data sources to uncover new insights about disease. This is Part 2 of a special 6-part series of episodes recorded at the AI Applications Summit produced in Boston by Corey Lane Partners in October 2018. How to rate MoneyBall Me…
 
Harry interviews Andrew A. Radin, co-founder and CEO of twoXAR, a Mountain View, CA-based AI-driven drug discovery startup that unifies disparate data to identify potential disease treatments. This episode is Part 1 of a 6-part special series recorded at the AI Applications Summit produced in Boston by Corey Lane partners in October 2018. How to ra…
 
Leapfrog Group president and CEO Leah Binder talks with Harry about data transparency and how it helps inform healthcare decisions by putting the right information in the hands of patients and employers. How to rate MoneyBall Medicine on iTunes with an iPhone, iPad, or iPod touch: Launch the "Podcasts" app on your device. If you can't find this app…
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login